Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2005 1
2006 9
2007 1
2008 3
2009 3
2010 3
2011 2
2012 6
2013 7
2014 6
2015 11
2016 16
2017 15
2018 6
2019 13
2020 21
2021 17
2022 10
2023 11
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

140 results

Results by year

Filters applied: . Clear all
Page 1
Gastric cancer.
Van Cutsem E, Sagaert X, Topal B, Haustermans K, Prenen H. Van Cutsem E, et al. Among authors: prenen h. Lancet. 2016 Nov 26;388(10060):2654-2664. doi: 10.1016/S0140-6736(16)30354-3. Epub 2016 May 5. Lancet. 2016. PMID: 27156933 Review.
Randomized trial of TAS-102 for refractory metastatic colorectal cancer.
Mayer RJ, Van Cutsem E, Falcone A, Yoshino T, Garcia-Carbonero R, Mizunuma N, Yamazaki K, Shimada Y, Tabernero J, Komatsu Y, Sobrero A, Boucher E, Peeters M, Tran B, Lenz HJ, Zaniboni A, Hochster H, Cleary JM, Prenen H, Benedetti F, Mizuguchi H, Makris L, Ito M, Ohtsu A; RECOURSE Study Group. Mayer RJ, et al. Among authors: prenen h. N Engl J Med. 2015 May 14;372(20):1909-19. doi: 10.1056/NEJMoa1414325. N Engl J Med. 2015. PMID: 25970050 Free article. Clinical Trial.
Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials.
Drilon A, Siena S, Dziadziuszko R, Barlesi F, Krebs MG, Shaw AT, de Braud F, Rolfo C, Ahn MJ, Wolf J, Seto T, Cho BC, Patel MR, Chiu CH, John T, Goto K, Karapetis CS, Arkenau HT, Kim SW, Ohe Y, Li YC, Chae YK, Chung CH, Otterson GA, Murakami H, Lin CC, Tan DSW, Prenen H, Riehl T, Chow-Maneval E, Simmons B, Cui N, Johnson A, Eng S, Wilson TR, Doebele RC; trial investigators. Drilon A, et al. Among authors: prenen h. Lancet Oncol. 2020 Feb;21(2):261-270. doi: 10.1016/S1470-2045(19)30690-4. Epub 2019 Dec 11. Lancet Oncol. 2020. PMID: 31838015 Free PMC article.
Sotorasib for previously treated colorectal cancers with KRASG12C mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial.
Fakih MG, Kopetz S, Kuboki Y, Kim TW, Munster PN, Krauss JC, Falchook GS, Han SW, Heinemann V, Muro K, Strickler JH, Hong DS, Denlinger CS, Girotto G, Lee MA, Henary H, Tran Q, Park JK, Ngarmchamnanrith G, Prenen H, Price TJ. Fakih MG, et al. Among authors: prenen h. Lancet Oncol. 2022 Jan;23(1):115-124. doi: 10.1016/S1470-2045(21)00605-7. Epub 2021 Dec 15. Lancet Oncol. 2022. PMID: 34919824 Clinical Trial.
The potential and controversy of targeting STAT family members in cancer.
Verhoeven Y, Tilborghs S, Jacobs J, De Waele J, Quatannens D, Deben C, Prenen H, Pauwels P, Trinh XB, Wouters A, Smits ELJ, Lardon F, van Dam PA. Verhoeven Y, et al. Among authors: prenen h. Semin Cancer Biol. 2020 Feb;60:41-56. doi: 10.1016/j.semcancer.2019.10.002. Epub 2019 Oct 9. Semin Cancer Biol. 2020. PMID: 31605750 Free article. Review.
Iron supplementation is sufficient to rescue skeletal muscle mass and function in cancer cachexia.
Wyart E, Hsu MY, Sartori R, Mina E, Rausch V, Pierobon ES, Mezzanotte M, Pezzini C, Bindels LB, Lauria A, Penna F, Hirsch E, Martini M, Mazzone M, Roetto A, Geninatti Crich S, Prenen H, Sandri M, Menga A, Porporato PE. Wyart E, et al. Among authors: prenen h. EMBO Rep. 2022 Apr 5;23(4):e53746. doi: 10.15252/embr.202153746. Epub 2022 Feb 24. EMBO Rep. 2022. PMID: 35199910 Free PMC article.
Podoplanin-Expressing Macrophages Promote Lymphangiogenesis and Lymphoinvasion in Breast Cancer.
Bieniasz-Krzywiec P, Martín-Pérez R, Ehling M, García-Caballero M, Pinioti S, Pretto S, Kroes R, Aldeni C, Di Matteo M, Prenen H, Tribulatti MV, Campetella O, Smeets A, Noel A, Floris G, Van Ginderachter JA, Mazzone M. Bieniasz-Krzywiec P, et al. Among authors: prenen h. Cell Metab. 2019 Nov 5;30(5):917-936.e10. doi: 10.1016/j.cmet.2019.07.015. Epub 2019 Aug 22. Cell Metab. 2019. PMID: 31447322 Free article.
Macrophage Metabolism Controls Tumor Blood Vessel Morphogenesis and Metastasis.
Wenes M, Shang M, Di Matteo M, Goveia J, Martín-Pérez R, Serneels J, Prenen H, Ghesquière B, Carmeliet P, Mazzone M. Wenes M, et al. Among authors: prenen h. Cell Metab. 2016 Nov 8;24(5):701-715. doi: 10.1016/j.cmet.2016.09.008. Epub 2016 Oct 20. Cell Metab. 2016. PMID: 27773694 Free article.
The Nitrogen Mustards.
Highley MS, Landuyt B, Prenen H, Harper PG, De Bruijn EA. Highley MS, et al. Among authors: prenen h. Pharmacol Rev. 2022 Jul;74(3):552-599. doi: 10.1124/pharmrev.120.000121. Pharmacol Rev. 2022. PMID: 35710137 Review.
Breast tumors interfere with endothelial TRAIL at the premetastatic niche to promote cancer cell seeding.
Riera-Domingo C, Leite-Gomes E, Charatsidou I, Zhao P, Carrá G, Cappellesso F, Mourao L, De Schepper M, Liu D, Serneels J, Alameh MG, Shuvaev VV, Geukens T, Isnaldi E, Prenen H, Weissman D, Muzykantov VR, Soenen S, Desmedt C, Scheele CLGJ, Sablina A, Di Matteo M, Martín-Pérez R, Mazzone M. Riera-Domingo C, et al. Among authors: prenen h. Sci Adv. 2023 Mar 22;9(12):eadd5028. doi: 10.1126/sciadv.add5028. Epub 2023 Mar 22. Sci Adv. 2023. PMID: 36947620 Free PMC article.
140 results